Piper Sandler Maintains Neutral on Globus Medical, Raises Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Matt O'Brien has maintained a Neutral rating on Globus Medical (NYSE:GMED) and increased the price target from $55 to $60.

May 08, 2024 | 4:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler maintains a Neutral rating on Globus Medical but raises the price target from $55 to $60.
The increase in price target by Piper Sandler suggests a positive outlook on the stock's value, potentially leading to short-term price appreciation. However, the Neutral rating indicates that the analyst sees the stock as fairly valued at current levels, which might temper significant price movement.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100